{"id":"imab","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL356597","moleculeType":"Small molecule","molecularWeight":"420.25"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"While specific molecular targets for iMAB variants under EORTC development are not universally documented in public sources, immunomodulatory antibodies in this class typically work by engaging immune checkpoints or activating immune effector cells to promote tumor recognition and destruction. The exact mechanism depends on the specific iMAB variant in phase 3 development.","oneSentence":"iMAB is an investigational immunomodulatory antibody designed to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:33.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under phase 3 evaluation by EORTC)"}]},"trialDetails":[{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT05890963","phase":"PHASE1","title":"10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Ho","startDate":"2023-11-28","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT04912063","phase":"PHASE1","title":"Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-06-25","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":40},{"nctId":"NCT03875209","phase":"PHASE1","title":"10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults","status":"COMPLETED","sponsor":"David Ho","startDate":"2019-04-08","conditions":"HIV-1-infection","enrollment":54},{"nctId":"NCT04895410","phase":"PHASE1","title":"Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2022-01-17","conditions":"Multiple Myeloma","enrollment":8},{"nctId":"NCT00255268","phase":"PHASE4","title":"CMAB vs IMAB in Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Metastatic Prostate Cancer","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATYPICAL FRACTURE"}],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["intermittent maximum androgen blockade"],"phase":"phase_3","status":"active","brandName":"iMAB","genericName":"iMAB","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"iMAB is an investigational immunomodulatory antibody designed to enhance anti-tumor immune responses. Used for Cancer (specific indication under phase 3 evaluation by EORTC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}